NASDAQ:EIGREiger Biopharmaceuticals Stock Price, Forecast & News

$13.19

+0.03 (+0.23 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$12.67

Now: $13.19▼

$13.26

50-Day Range

$5.40

MA: $8.70▼

$13.16

52-Week Range

$4.55

Now: $13.19▼

$15.82

Volume310,052 shs

Average Volume462,821 shs

Market Capitalization$330.54 million

P/E RatioN/A

Dividend YieldN/A

Beta1.4

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Eiger Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.18, Eiger Biopharmaceuticals has a potential upside of 83.3% from its current price of $13.19.
Amount of Analyst Coverage
Eiger Biopharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Eiger Biopharmaceuticals has received 401 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eiger Biopharmaceuticals has received 275 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eiger Biopharmaceuticals has received 59.32% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote “Outperform” if you believe EIGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Eiger Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Eiger Biopharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eiger Biopharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.50% of the stock of Eiger Biopharmaceuticals is held by insiders.
Percentage Held by Institutions
76.44% of the stock of Eiger Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Eiger Biopharmaceuticals are expected to grow in the coming year, from ($1.73) to ($1.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eiger Biopharmaceuticals is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eiger Biopharmaceuticals is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eiger Biopharmaceuticals has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EIGR

Previous Symbol

CUSIPN/A

CIK1305253

Webwww.eigerbio.com

Phone650-272-6138

Debt

Debt-to-Equity Ratio0.74

Current Ratio6.14

Quick Ratio6.14

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.31 per share

Price / Book5.71

Profitability

EPS (Most Recent Fiscal Year)($3.08)

Net Income$-70,250,000.00

Net MarginsN/A

Return on Equity-105.31%

Return on Assets-61.19%

Miscellaneous

Employees18

Outstanding Shares25,060,000

Market Cap$330.54 million

Next Earnings Date8/13/2020 (Estimated)

OptionableNot Optionable

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

How has Eiger Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EIGR shares have increased by 93.7% and is now trading at $13.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eiger Biopharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eiger Biopharmaceuticals.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eiger Biopharmaceuticals.

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.14. View Eiger Biopharmaceuticals' earnings history.

What price target have analysts set for EIGR?

5 brokerages have issued 1-year target prices for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $33.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $24.18 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price. View analysts' price targets for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:

1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (1/27/2020)
2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

Press coverage about EIGR stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 1.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutEiger Biopharmaceuticals.

Who are some of Eiger Biopharmaceuticals' key competitors?

Some companies that are related to Eiger Biopharmaceuticals include Beam Therapeutics (BEAM), Translate Bio (TBIO), Coherus Biosciences (CHRS), NanoString Technologies (NSTG), Passage Bio (PASG), Sorrento Therapeutics (SRNE), Compugen (CGEN), Krystal Biotech (KRYS), Orchard Therapeutics (ORTX), Cellectis (CLLS), Atara Biotherapeutics (ATRA), BioCryst Pharmaceuticals (BCRX), Proteon Therapeutics (PRTO), BAVARIAN NORDIC/S (BVNRY) and Replimune Group (REPL). View all competitors.

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Exelixis (EXEL).

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the following people:

Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger Biopharmaceuticals' major shareholders?

Eiger Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.59%), Vivo Capital LLC (7.15%), Cormorant Asset Management LP (3.25%), State Street Corp (1.83%), Soleus Capital Management L.P. (1.62%) and P.A.W. Capital Corp (1.47%). Company insiders that own Eiger Biopharmaceuticals stock include David A Cory, Eldon C Mayer III, Interwest Partners X Lp, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz. View institutional ownership trends for Eiger Biopharmaceuticals.

Which institutional investors are selling Eiger Biopharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, JPMorgan Chase & Co., BlackRock Inc., Cormorant Asset Management LP, Morgan Stanley, New York State Common Retirement Fund, Victory Capital Management Inc., and Victory Capital Management Inc.. View insider buying and selling activity for Eiger Biopharmaceuticals.

Which institutional investors are buying Eiger Biopharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, P.A.W. Capital Corp, Soleus Capital Management L.P., Nuveen Asset Management LLC, Two Sigma Advisers LP, Voss Capital LLC, Two Sigma Investments LP, and Trellus Management Company LLC. Company insiders that have bought Eiger Biopharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz. View insider buying and selling activity for Eiger Biopharmaceuticals.

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $13.19.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $330.54 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is www.eigerbio.com.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff